aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

SAN FRANCISCO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- On September 15, 2025, investors in aTyr Pharma, Inc. (NASDAQ: ATYR) saw the price of their shares crater over 80% after the company reported that its late-stage study of efzofitimod for treating pulmonary sarcoidosis, a significant type of interstitial lung disease (“ILD”), did not meet its main goal. The development and severe market reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether aTyr may have misled investors about the Phase 2 data and its Phase 3 EFZO-FIT™ trial design. The firm urges investors in aTyr who suffered significant losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/atyr Contact the Firm Now: ATYR@hbsslaw.com 844-916-0895 aTyr Pharma, Inc. (AYTR) Investigation: The investigation is focused on the propriety of aTyr’s disclosures about the quality of its Phase 2 efzofitimod data and its Phase 3 EFZO-FIT™ trial design. aTyr assured investors that “the data that we […] produced in Phase 2 was some of the best data that the experts have ever seen[,]” and, as to ILD, “[e]fzofitimod can own that market” (which the company has repeatedly quantified as a multi-billion-dollar opportunity). Investors’ expectations were dashed on September 15, 2025, when aTyr convened its EFZO-FIT™ topline results call. The company announced that topline results failed to meet their primary endpoint of steroid reduction after a year of forced tapering and said that “we did not achieve statistical significance as the placebo tapering outperformed even our most aggressive modeling.” The market’s response was brutal, sending the price of aTyr shares down over 80% that day amid a flood of analyst downgrades. “We’re investigating whether aTyr may have misled investors about its data and trial design while emphasizing a multi-billion-dollar market opportunity,” said Reed Kathrein, the Hagens Berman partner leading the investigation. If you invested in aTyr and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now » If you’d like more information and answers to frequently asked questions about the aTyr investigation, read more » Whistleblowers: Persons with non-public information regarding aTyr should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ATYR@hbsslaw.com. About Hagens BermanHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895

aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT™ Study Failure Drives Shares 80% Lower -- Hagens Berman

FAQ

Why Very Bearish?

How important is it?

Why Long Term?

Related Companies

Related News